For a new list of recommended reading from our Emerging Scholars Advisory Committee, <<click here>> 

Welcome to Hepatitis Delta Connect!

A dedicated program of the Hepatitis B Foundation to increase awareness about hepatitis delta - a serious virus that coinfects hepatitis B patients - and to promote screening and testing, and provide information and support for those affected. 

Copy of Website transmission graphic asian african blended

    Clinical Trial Finder - Find A Clinical Trial Near You! 

          hepbfoundation hepdelta banner 2            

Watch our latest webinar! 

HDV Webinar Snip

Hep Delta Patient and Provider Surveys FB IG

We would love to hear from you! Complete the survey to sign up!

Hep Delta Patient and Provider Surveys FB IG 3

Take our brief survey & sign up to receive updates on clinical trials, info about hepatitis delta monitoring, management & care + more! Sign up today!

Am i at risk
Newly Diagnosed png

Website map by users2

We've educated 13,000 people in 111 countries!


News & Updates

March 2021 Blog Post: Hepatitis B and Hepatitis Delta

January 2021 Blog Post: Eiger Presents Clinical Trial Results at The Liver Meeting Digital Experience™ 2020

September 2020 Blog Post: New Hepatitis Delta Treatment Approved by European Commission

May 2020 Blog Post: Does Hepatitis Delta Increase My Risk for Liver Cancer?

View our recent webinar, Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies? recording here.

01/04/2022: New Slideset Updated on Don't Delay with Delta: Best Practices and Calls to Action in HDV
12/21/2021: Bulevirtide Improves Quality of Life in Chronic HDV
12/21/2021: Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection
12/20/2021: Medical Minutes Podcasts on HDV Epidemiology and Universal Screening
12/18/2021: Large Proportion of Undiagnosed Anti-HDV Positive Individuals Due to Lack of Testing
12/16/2021: UN Introduces Resolution on Rare Diseases
12/13/2021: Bulevirtide Shows Real-World Efficacy Versus HDV
12/03/2021: Should We Screen All Patients with Hepatitis B for Hepatitis Delta?
12/01/2021: Hepatitis Delta Presentations from the 2021 AASLD Liver Meeting Now Available
12/01/2021: Ethnic Variations in Clinical Presentation and Treatment Eligibility for HDV Infection at a US Referral Center
11/19/2021: Gilead Files BLA for Bulevirtide to Treat Chronic HDV Infection
11/12/2021: Prevalence and Characteristics of Hepatitis Delta in the United States: An Analysis of All-Payer Claims Databases
09/29/2021: The Kinesin KIF4 Mediates HBV/HDV Entry Through Regulation of Surface NTCP Localization and Can Be Targeted by RXR Agonists in vitro
08/24/2021: The Highly Complementary Model of Hepatitis D and Hepatitis B, Described by Scientists, Can Broadly Cover the HDV Replication Cycle
07/28/2021: Hepatitis D: Neglected Disease in the Race to Eliminate Viral Hepatitis by 2030
07/27/2021: Risk of Hepatocellular Carcinoma in Hepatitis B & D Virus Co-Infected Patients: A Systematic Review and Meta-Analysis of Longitudinal Studies
07/12/2021: Significant Disparities in the International Incidence of Hepatitis Delta Virus
06/25/2021: Gilead Preps Filing for Hepatitis D Therapy Hepcludex in US
06/24/2021: Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
04/01/2021: Hepatitis Delta Infection Among Persons with HIV in Europe
Get Connected

square facebook 512Twitter icon horizontal2instagram icon

Contact us button2